Could JAK Inhibitors Improve Ankylosing Spondylitis Treatment?

Short version: JAK inhibitors are the “newer kids” on the ankylosing spondylitis (AS) blockoral, targeted, and backed by strong clinical trial results. They won’t replace exercise, NSAIDs, or biologics for everyone, but for the right patient, they can absolutely level up the treatment playbook.

Important note: This article is for educationnot personal medical advice. AS is a “choose-your-own-adventure” disease (except no one asked for this adventure), so decisions should be made with a rheumatologist.

Ankylosing Spondylitis in 2026: Same Disease, Better Tools

Ankylosing spondylitis is a form of axial spondyloarthritisa chronic inflammatory condition that primarily targets the spine and sacroiliac joints. It can also bring friends you didn’t invite: enthesitis (tendon/ligament insertion pain), peripheral joint swelling, and extra issues like uveitis (eye inflammation), psoriasis, and inflammatory bowel disease.

AS isn’t “just back pain.” It’s back pain with a personality: typically worse with rest, better with movement, and often paired with morning stiffness and fatigue. The long-term worry is inflammation-driven damageplus the way pain and stiffness can quietly shrink your world (work, sleep, exercise, social life… basically the fun stuff).

The Current Treatment Ladder (a.k.a. “Step One: Keep the Spine From Acting Like a Rusty Hinge”)

1) Movement is medicine (yes, really)

Regular exercise, stretching, and physical therapy remain foundational. This is not a motivational posterit’s physiology. Keeping mobility and posture strong can reduce stiffness and help function over time.

2) NSAIDs: the classic first-line option

Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly the first pharmacologic step for AS symptoms. Many people improve meaningfullyespecially early onthough not everyone can tolerate them long-term, and not everyone gets enough relief.

3) Biologics: TNF inhibitors and IL-17 inhibitors

If NSAIDs don’t cut it (or can’t be used), many patients move to biologic therapies like TNF inhibitors or IL-17 inhibitors. These have been game-changers. The catch? They’re injections/infusions, and some people still don’t respond wellor stop responding over time.

4) Now entering the chat: JAK inhibitors

JAK inhibitors bring a new option: targeted immune signaling control in a pill. That convenience matters. So does the biology. The question is whether that translates into better outcomesand for which patients.

What Are JAK Inhibitors, and Why Might They Help in AS?

“JAK” stands for Janus kinase, part of the JAK-STAT pathwayone of the immune system’s major signal relays. Cytokines (chemical messengers) bind to receptors on immune cells, JAK enzymes transmit the signal, and inflammation-related genes get switched on like a stadium light show.

JAK inhibitors reduce inflammatory signaling by blocking specific JAK enzymes (different drugs have different selectivity). In AS, that can mean less inflammatory back pain, improved mobility, and better overall disease activity scores.

Think of it like this: biologics often block a single “headline” cytokine (like TNF). JAK inhibitors can dampen multiple inflammatory signals downstream. That broader effect may be part of why they work for certain people who don’t do well on other medications.

Which JAK Inhibitors Matter for Ankylosing Spondylitis?

In the U.S., two names come up most often in AS conversations:

• Tofacitinib (brand: Xeljanz / Xeljanz XR)
• Upadacitinib (brand: Rinvoq)

Both are oral medications andbased on FDA labelingare indicated for adults with active AS who have had an inadequate response or intolerance to at least one TNF blocker. (Translation: typically not the first “advanced” therapy after NSAIDs, but an option when TNF inhibitors don’t work out.)

Other JAK inhibitors have been studied across spondyloarthritis conditions globally, but U.S. practice is currently most shaped by the drugs above and their labeling, evidence base, and safety guidance.

What the Clinical Trials Say: Do JAK Inhibitors Actually Work?

Clinical trials in AS frequently use outcomes like ASAS40 (a meaningful symptom improvement measure), pain scores, function indices, and MRI inflammation metrics.

Upadacitinib: strong results, including in “treatment-refractory” AS

In a major phase 3 trial of adults with active AS who had inadequate response to biologics (including TNF or IL-17 inhibitors), upadacitinib produced significantly higher response rates than placebo at 14 weeks. For example, ASAS40 response was 45% with upadacitinib vs 18% with placebo at week 14 in one key study population.

Trials and extensions also report improvements in pain, function, and MRI inflammation. Longer-term follow-up suggests sustained benefit for many patients who stay on therapy, though real-life durability can vary (because humans are not randomized controlled trials).

Tofacitinib: meaningful symptom improvement vs placebo

Tofacitinib has also demonstrated significant clinical benefits in AS trials. In a phase 3 study, response rates at week 16 favored tofacitinib over placebo (including improvements on ASAS20 and ASAS40), supporting it as a legitimate option when earlier therapies aren’t enough.

So… are JAK inhibitors better than TNF or IL-17 inhibitors?

Not automatically. TNF inhibitors and IL-17 inhibitors have longer track records in AS, and many patients do very well on them. JAK inhibitors aren’t “the new superior everything.” They’re more like a powerful new lane on the highwayespecially valuable for people who:

• didn’t respond well to TNF inhibitors (or couldn’t tolerate them),
• prefer an oral medication over injections/infusions,
• have persistent symptoms despite multiple prior therapies,
• need a different mechanism due to disease features or treatment history.

Where JAK Inhibitors Might Fit Best in Real Treatment Plans

In U.S. practice, a common sequence looks like:

1. Exercise/physical therapy + NSAIDs
2. TNF inhibitor (often first biologic choice)
3. Switch TNF inhibitor or try IL-17 inhibitor (depending on response and comorbidities)
4. Consider JAK inhibitor when response is inadequate or side effects/constraints limit options

But treatment isn’t a neat ladderit’s more like a subway map with transfers. For example:

• Needle fatigue is real: Some patients are excellent candidates for an oral option after years of injections.
• Extra symptoms matter: Eye, skin, and gut involvement can influence whether a TNF inhibitor, IL-17 inhibitor, or JAK inhibitor makes the most sense.
• Work/life logistics matter: If frequent infusions or injection storage is a barrier, an oral medication may improve adherence (and adherence improves outcomes).

Safety: The Part You Should Not Skip

JAK inhibitors can be highly effectivebut they come with serious safety considerations. The FDA requires boxed warnings on JAK inhibitors about increased risk of serious infections and other major risks (including certain cardiovascular events, blood clots, malignancy, and mortality) based on safety data in higher-risk populations.

Common “before you start” checklist

• Screening: TB testing and often hepatitis screening before starting
• Vaccines: many clinicians strongly consider recombinant shingles vaccination (Shingrix) if eligible
• Baseline labs: CBC, liver enzymes, and lipids are commonly checked

Ongoing monitoring (because “set it and forget it” is for slow cookers, not immunology)

Clinicians often monitor blood counts, liver enzymes, and lipids periodically, and watch closely for infections. People with certain risk factors (older age, cardiovascular risk, smoking history, prior clots, or malignancy history) may require extra caution or a different therapy choice.

Practical tip: If you’re considering a JAK inhibitor, bring a one-page list of your medical history, vaccines, and prior AS meds to your appointment. It speeds up decision-making and reduces “wait… when was your last TB test?” energy.

Questions to Ask Your Rheumatologist (Steal This Script)

• Based on my history, would you consider a JAK inhibitor nowor later?
• What’s my personal risk profile for infection, clots, or heart disease?
• Which monitoring labs will I need, and how often?
• Should I get Shingrix or other vaccines before starting?
• If this works, what does “success” look likepain, function, MRI, ASDAS, or all of the above?
• What’s the plan if I improve but don’t reach low disease activity?

Real-World Experiences (About ): What It’s Like When a JAK Inhibitor Enters the Routine

Clinical trials can tell you whether a medication works. Real life tells you what it’s like to live on itMonday mornings, travel days, pharmacy calls, and that moment you realize you’ve built a small shrine to pill organizers.

1) People often notice the “logistics relief” first. For patients who have spent years juggling injection schedules, refrigeration requirements, sharps disposal, or infusion appointments that mysteriously land on the busiest workdays, an oral pill can feel like a quality-of-life upgrade before symptoms even change. That convenience can translate into better consistencybecause the best medication is the one you can actually take on time.

2) Symptom changes can be subtle at first, then obvious. Many patients describe early improvements as “less background noise”: morning stiffness eases, sleep becomes less interrupted, and daily movement feels less like negotiating with a stubborn door hinge. Others feel a quicker, clearer difference in back pain or fatigue. The key real-world lesson: clinicians and patients often track outcomes with both numbers (pain scales, ASDAS/BASDAI) and lived markerslike “I can sit through a movie without plotting my escape route.”

3) Monitoring becomes part of the rhythm. JAK inhibitors tend to come with a lab scheduleblood counts, liver enzymes, lipidsespecially early on. In practice, patients who do best are the ones who treat lab work like routine maintenance rather than a once-a-year surprise. Many clinics set reminders, bundle labs with other appointments, or use standing orders so patients aren’t stuck in paperwork limbo.

4) Infection-awareness goes up (without needing to live in a bubble). People commonly become more intentional about basics: staying current on vaccines, not ignoring fevers, and calling early when something feels off. Some patients report being more mindful during peak respiratory virus seasons. The goal isn’t to be fearfulit’s to be prepared. This is also where shingles vaccination conversations often show up, because shingles risk is a known concern with this class of medications.

5) Insurance and prior authorization can be the hidden boss level. A frustrating but common experience is that access takes timedocumentation of prior treatments, proof of inadequate response, and back-and-forth approvals. Patients who keep a simple timeline (what they tried, when, and what happened) often move through this faster. Many also lean on specialty pharmacies or manufacturer support programs when eligible.

Bottom line from the “real world”: When a JAK inhibitor works for AS, people often describe a combined winless inflammation and a treatment routine that fits life better. The trade-off is that safety monitoring and risk assessment matter more than ever, and the best outcomes usually come from a tight partnership between patient and rheumatology team.

So, Could JAK Inhibitors Improve Ankylosing Spondylitis Treatment?

Yesfor many patients, JAK inhibitors can be a meaningful improvement in the AS toolkit, especially after TNF inhibitors (and sometimes IL-17 inhibitors) haven’t delivered enough relief or aren’t feasible. They offer a powerful combination of targeted immune control and oral convenience, backed by strong trial data showing significant symptom and function improvements.

But they’re not a casual add-on. Because of class-wide safety warnings and the need for screening and monitoring, the best use of JAK inhibitors is personalized: the right medication, for the right patient, at the right time, with the right guardrails.